Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain

BACKGROUND: Respiratory syncytial virus (RSV) infection remains one of the major reasons of re-hospitalization among children with congenital heart disease (CHD). This study estimated the cost-effectiveness of palivizumab prophylaxis versus placebo, in Spain, from the societal perspective, using a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Ralph, Majer, Istvan, García Román, Natalia, Rivas Basterra, Alejandra, Grubb, ElizaBeth, Medrano López, Constancio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736509/
https://www.ncbi.nlm.nih.gov/pubmed/29260345
http://dx.doi.org/10.1186/s13561-017-0181-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736509/
https://www.ncbi.nlm.nih.gov/pubmed/29260345
http://dx.doi.org/10.1186/s13561-017-0181-3

Ejemplares similares